8 completed, 7 unknown, 1 enrolling by invitation, 1 suspended. 8 Phase 3, 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 4, Unknown 3, Suspended 1 |
| Not applicable | 2 | Completed 1, Enrolling by invitation 1 |
| Phase 2 | 1 | Completed 1 |
Follow Tuberculosis Research Centre, India: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Urine Isoniazid Testing to Detect Nonadherence to Tuberculosis Medications in India Urine isoniazid testing (IsoScreen test) - Tuberculosis, Pulmonary, Medication Adherence | Not applicable | Enrolling by invitation | Tufts University | 900 | 2026-04-07 | 2026-06-04 |
| BCG Revaccination in Children and Adolescents BCG vaccine, Oral Chemoprophylaxis - Tuberculosis Infection, Tuberculosis | Phase 3 | Suspended | Tuberculosis Research Centre, India | 9200 | 2024-07-15 | 2023-12-18 |
| Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients Isoniazid, Rifampicin, Pyrazinamide - Tuberculosis, Pulmonary | Completed | Tuberculosis Research Centre, India | 550 | 2022-03-15 | 2026-09-16 | |
| Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India Linezolid, Bedaquiline, Pretomanid - Pre-Extensively Drug-Resistant Pulmonary TB, Treatment Intolerant Multidrug-Resistant Pulmonary TB | Phase 3 | Unknown | Tuberculosis Research Centre, India | 400 | 2021-10-07 | 2024-01-03 |
| Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis COVID-19 Respiratory Infection, Pulmonary Tuberculoses | Unknown | Tuberculosis Research Centre, India | 250 | 2021-06-21 | 2023-11-22 | |
| Characterization and Durability of COVID-19 Vaccine Induced Immune Responses in Healthcare/Frontline Workers Covid19 | Completed | Tuberculosis Research Centre, India | 132 | 2021-05-07 | 2023-11-29 | |
| Comorbidities and Coinfections in Latent TB Latent Tuberculosis, Diabete Mellitus | Unknown | Tuberculosis Research Centre, India | 300 | 2021-04-19 | 2023-11-22 | |
| MISC COVID-19 Study in Pediatric Population SARS-CoV2 Infection, Multisystem Inflammatory Syndrome in Children | Unknown | Tuberculosis Research Centre, India | 180 | 2020-12-23 | 2024-05-30 | |
| The Impact of Malnutrition on Immune Responses to Tuberculosis Ready to Use supplementary food (RUSF) - Malnutrition, Child, Tuberculosis | Unknown | Tuberculosis Research Centre, India | 200 | 2020-08-01 | 2024-05-29 | |
| BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots BCG vaccine (Freeze-dried) - COVID | Phase 3 | Completed | Tuberculosis Research Centre, India | 2175 | 2020-07-01 | 2022-07-08 |
| Latency in Pulmonary Tuberculosis Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol - Pulmonary Tuberculosis | Phase 3 | Completed | Tuberculosis Research Centre, India | 120 | 2010-02-01 | 2021-04-19 |
| Addressing Psychosocial Needs and HIV Risk in Indian MSM Behavioral intervention - HIV/STI Risk, HIV/STI Incidence | Not applicable | Completed | Massachusetts General Hospital | 96 | 2010-01-01 | 2015-06-01 |
| Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis ATT (Ethambutol, Pyrazinamide, INH, Rifampicin) - HIV Infection, Pulmonary TB | Phase 3 | Completed | Tuberculosis Research Centre, India | 331 | 2009-09-14 | 2019-04-10 |
| Effect of Albendazole Dose on Clearance of Filarial Worms DEC/Albendazole - Lymphatic Filariasis, Wuchereria Bancrofti Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1000 | 2006-09-09 | 2017-07-02 |
| Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment Didanosine, Lamivudine, Efavirenz, Didanosine, Lamivudine, Nevirapine - Tuberculosis, Human Immunodeficiency Virus Infections | Phase 3 | Unknown | Tuberculosis Research Centre, India | 180 | 2006-06-01 | 2009-10-08 |
| Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) - Tuberculosis, Human Immunodeficiency Virus Infections | Phase 3 | Unknown | Tuberculosis Research Centre, India | 300 | 2001-02-01 | 2008-06-11 |
| Preventive Therapy for Tuberculosis in HIV Infected Persons Isoniazid with Ethambutol - Human Immunodeficiency Virus, Tuberculosis | Phase 3 | Completed | Tuberculosis Research Centre, India | 683 | 2001-02-01 | 2024-05-22 |
Tuberculosis (5) · Tuberculosis, Pulmonary (5) · COVID-19 (2) · HIV Infections (2) · Latent Tuberculosis (2) · Malnutrition (2) · Acquired Immunodeficiency Syndrome (1) · Child Nutrition Disorders (1) · Diabetes Mellitus (1) · Elephantiasis, Filarial (1) · Enterobiasis (1) · Medication Adherence (1) · Trematode Infections (1) · pediatric multisystem inflammatory disease, COVID-19 related (1)
Ethambutol (5) · Isoniazid (5) · Pyrazinamide (3) · Rifampin (3) · BCG Vaccine (2) · Moxifloxacin (2) · Behavior Therapy (1) · Chemoprevention (1) · Didanosine (1) · Freeze Drying (1) · Lamivudine (1) · Linezolid (1) · Nevirapine (1) · Protons (1) · Psychosocial Intervention (1)
India (17) · United States (1)
Subash Babu, MBBS, PhD (3) · Aishwarya Venkataraman, MRCPCH (2) · Soumya Swaminathan, MD (2) · Soumya Swaminathan, MD MNAMS (2) · Anant Mohan (1) · Anuradha Rajamanickam, PhD (1) · Asha Keetharam (1) · Beena E. Thomas, PhD (1) · Hemant Deshmukh (1) · Kamalesh Sarkar (1) · Narendran Gopalan, DNB (Chest) (1) · PR Narayanan, PhD (1)
PMID 19965813, PMID 21890776, PMID 23251327, PMID 25156114, PMID 25363329, PMID 26095067, PMID 29507938, PMID 30993478, PMID 34691079, PMID 36038181, PMID 36252397, PMID 36322537
R21MH085314 (1)